Regulus Therapeutics

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

San Diego, US
Size (employees)
97 (est)+2%
Regulus Therapeutics was founded in 2007 and is headquartered in San Diego, US

Key People at Regulus Therapeutics

David Baltimore

David Baltimore


Regulus Therapeutics Office Locations

Regulus Therapeutics has an office in San Diego
San Diego, US (HQ)
10614 Science Center Dr

Regulus Therapeutics Data and Metrics

Regulus Therapeutics Financial Metrics

Regulus Therapeutics's revenue was reported to be $1.2 m in FY, 2016 which is a 94% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

1.2 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(81.8 m)

EBIT (FY, 2016)

(81.5 m)

Market capitalization (26-May-2017)

73.1 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

14.9 m
Regulus Therapeutics's current market capitalization is $73.1 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


19.6 m7.7 m20.8 m1.2 m

Revenue growth, %


Operating expense total

37.4 m52.6 m75.5 m82.7 m


(17.8 m)(44.9 m)(54.8 m)(81.5 m)

EBIT margin, %


Pre tax profit

(18.7 m)(56.7 m)(55.8 m)(81.8 m)

Net Income

(18.7 m)(56.7 m)(55.7 m)(81.8 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


17.8 m37.3 m16 m14.9 m

Current Assets

117.2 m165 m134.3 m87.5 m


3.8 m3.6 m5.4 m11.8 m

Total Assets

123.1 m171.5 m141.1 m100.7 m

Accounts Payable

1.2 m2.2 m2.7 m5.8 m

Current Liabilities

10.4 m35.2 m12.6 m13.8 m

Additional Paid-in Capital

172.5 m267.9 m315.7 m329.5 m

Retained Earnings

(79.1 m)(135.8 m)(191.5 m)(273.4 m)

Total Equity

93.5 m132 m124.1 m56.1 m

Financial Leverage

1.3 x1.3 x1.1 x1.8 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.7 m)(56.7 m)(55.7 m)(81.8 m)

Depreciation and Amortization

1.4 m1.5 m1.6 m2.3 m

Accounts Payable

860 k940 k529 k3.1 m

Cash From Operating Activities

(28.3 m)(39.5 m)(49.9 m)(56.9 m)

Purchases of PP&E

(800 k)(1.1 m)(1.4 m)(913 k)

Cash From Investing Activities

(40.9 m)(29.2 m)21.5 m35.3 m

Cash From Financing Activities

46.5 m88.2 m7 m20.6 m

Interest Paid

37 k39 k(27 k)(981 k)

Income Taxes Paid

1 k1 k(1 k)(1 k)
Numbers are in $, USDY, 2016


12.4 k

Financial Leverage

1.8 x

Regulus Therapeutics Operating Metrics

FY, 2016

Patents Issued


Regulus Therapeutics Market Value History

Regulus Therapeutics Online and Social Media Presence

Regulus Therapeutics News and Updates

Regulus Therapeutics Company Life and Culture

You may also be interested in